You just read:

MabVax Therapeutics Receives U.S. Patent for Fully Human Antibodies Targeting the Antigen GD2 Expressed on Sarcoma, Melanoma, and Neuroblastoma

News provided by

MabVax Therapeutics Holdings, Inc.

May 17, 2018, 08:45 ET